PET in Lymphoma

摘要: The management approach in Hodgkin (HL) and high-grade non-Hodgkin lymphomas (NHLs) has shifted toward reducing the toxicity long-term adverse effects associated with treatment while maintaining favorable outcomes low-risk patients. availability of more effective therapies for lymphoma provides a rationale accurate diagnostic tests updated patient evaluation, staging, response criteria. In this regard, positron emission tomography (PET) using fluorodeoxyglucose (FDG) computed (CT) proved as metabolic imaging tool compelling evidence supporting its superiority over conventional modalities, particularly staging early evaluation response, is now integrated into routine restaging algorithm lymphomas. A semiquantitative parameter measuring tumor glucose metabolism, maximum standardized uptake value (SUVmax), reflects aggressiveness neoplasm proven to be an important survival predictor. Several quantitative metrics including volume (MTV) total lesion glycolysis (TLG) appears dependable reproducible prognostic indicators. Additionally, 5-point Deauville score (DS) been recommended qualitative method evaluating interim end-of-treatment PET/CT results. This chapter summarizes data on potential utility assessment, restaging, describing current limitations modality.